Tafluprost
As of the edition of 20 October 2026, Tafluprost is a small molecule: marketed, first approved in 2008 (ES); acts on PTGFR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Small molecule
- Brand name
- Zioptan
- First approved
- 17 September 2008 (ES)
- Approvals on record
- 7 in 4 regions
- Holder of the most recent approval
- Santen Pharmaceutical; 3 holders in all
- Registered trials
- 20, 0 stopped early
- Disease areas
- Eye
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Tafluprost.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGFR | Prostaglandin F2-alpha receptor | P43088 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 7 | 7 | 0 | 0 |
| Phase 4 | 8 | 6 | 0 | 0 |
| All trials | 20 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Santen Pharmaceutical | Applicant and Lead sponsor of trials | 2008 to now |
| Merck & Co. | Applicant and Lead sponsor of trials | 2010 to now |
| Thea Pharma | Acquired holder | 2022 to now |